GSK, Endometrial Cancer and European Commission
EU approves endometrial, lung cancer drugs from GSK and J&J
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first-line treatment for locally advanced and metastatic NSCLC with exon 19 deletions or exon 21 L858R substitutions.
The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...
Hosted on MSN3h
New Breast Cancer Drug Kills Mouse Tumors In Single DoseThe typical treatment for estrogen receptor positive (ER+) breast cancer involves surgery and years of hormone therapy that ...
—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known ...
For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...
Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback